Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Harvard Bioscience, Inc. HBIO

Healthcare  —  Medical Instruments & Supplies
7.96 (0.06) (0.75%) as of 25 Sep
Market cap
$36.5M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Harvard Bioscience, Inc. (HBIO) Business Profile

Updated before January 2025

Company Overview

Harvard Bioscience, Inc. (HBIO) is a global developer, manufacturer, and marketer of a broad range of specialized products used to advance life science research and regenerative medicine. Founded in 1901, the company has a long-standing history of innovation and commitment to supporting scientific discovery. Headquartered in Holliston, Massachusetts, HBIO operates with a global footprint, serving customers in over 100 countries. The company is led by a team of experienced executives, including James Green, who serves as the President and Chief Executive Officer. Under his leadership, HBIO has focused on expanding its product portfolio and strengthening its position in the life sciences market.

Core Business Segments

Harvard Bioscience operates through several core business segments, each catering to specific needs within the life sciences and biomedical research industries. These segments include:

1. Preclinical Systems

HBIO provides advanced preclinical systems that are used in drug discovery and development. These systems include:

  • Physiological Monitoring Systems: Devices for monitoring cardiovascular, respiratory, and neurological functions in preclinical research.
  • Behavioral Research Tools: Equipment for studying animal behavior and cognition.

2. Cellular and Molecular Technologies

This segment focuses on tools and technologies for cellular and molecular biology research. Key products include:

  • Electrophysiology Equipment: Instruments for studying electrical properties of cells and tissues.
  • Microplate Readers: Devices for analyzing biological samples in high-throughput formats.
  • Cell Culture Systems: Solutions for growing and maintaining cells in laboratory settings.

3. Regenerative Medicine

HBIO is a leader in regenerative medicine, offering products that support tissue engineering and cell therapy. These include:

  • Bioreactors: Systems for growing tissues and cells in controlled environments.
  • Scaffolds: Materials used to support the growth of new tissues.

4. Contract Manufacturing and Custom Solutions

HBIO also provides contract manufacturing services and custom solutions for clients with specific research needs. This includes:

  • OEM Services: Manufacturing products under private labels for other companies.
  • Custom Instrumentation: Tailored solutions for unique research applications.

Business Model

Harvard Bioscience operates on a diversified business model that integrates product development, manufacturing, and customer support. The company generates revenue through the sale of its products, as well as through service contracts and custom solutions. HBIO’s approach emphasizes:

  • Innovation: Continuous investment in research and development to bring new products to market.
  • Customer-Centricity: Providing tailored solutions and exceptional customer service.
  • Global Reach: Leveraging its international distribution network to serve a diverse customer base.

Strategic Direction

HBIO is focused on driving growth through innovation and strategic investments. Key elements of its strategic direction include:

  • Expansion of Product Portfolio: Developing new products and enhancing existing ones to meet evolving customer needs.
  • Sustainability Goals: Implementing environmentally friendly practices in manufacturing and product design.
  • Market Penetration: Increasing its presence in emerging markets and expanding its customer base.
  • Digital Transformation: Leveraging digital technologies to improve operational efficiency and customer engagement.

Competitive Landscape

Harvard Bioscience operates in a highly competitive market, facing competition from both large multinational corporations and specialized niche players. Key competitors include:

  • Thermo Fisher Scientific: A global leader in life sciences tools and services.
  • Bio-Rad Laboratories: Known for its innovative products in molecular biology and clinical diagnostics.
  • Agilent Technologies: A major player in analytical instruments and laboratory solutions.
  • Smaller Niche Companies: Specialized firms offering unique products in specific research areas.

Risk Factors

Like any business, HBIO faces several risks that could impact its operations and financial performance. These include:

  • Market Dependence: Reliance on the life sciences and biomedical research markets, which are subject to funding fluctuations.
  • Supply Chain Disruptions: Potential delays or shortages in raw materials and components.
  • Regulatory Challenges: Compliance with stringent regulations in different countries.
  • Technological Obsolescence: The need to keep pace with rapid advancements in technology.

Recent Developments

Harvard Bioscience has made significant strides in recent years, including:

  • New Product Launches: Introduction of advanced electrophysiology systems and next-generation bioreactors.
  • Strategic Acquisitions: Acquiring companies to expand its product portfolio and market reach.
  • Global Expansion: Establishing new distribution partnerships in Asia and Latin America.
  • COVID-19 Impact: Adapting to challenges posed by the pandemic, including supply chain disruptions and shifts in research priorities.

Investment Considerations

Investors considering HBIO should weigh the following factors:

Strengths

  • Strong Brand Reputation: Over a century of experience and a trusted name in the industry.
  • Diverse Product Portfolio: Broad range of products catering to various research needs.
  • Global Presence: Access to international markets and a diverse customer base.
  • Innovation-Driven: Commitment to research and development.

Risks

  • Market Volatility: Dependence on research funding, which can be unpredictable.
  • Competitive Pressure: Intense competition from larger players and niche companies.
  • Regulatory Risks: Compliance with complex and evolving regulations.

Conclusion

Harvard Bioscience, Inc. is a well-established player in the life sciences and biomedical research markets. With a strong focus on innovation, customer-centricity, and global reach, the company is well-positioned for future growth. However, it must navigate challenges such as market volatility and regulatory compliance to maintain its competitive edge. Overall, HBIO offers a compelling investment opportunity for those seeking exposure to the life sciences sector.